#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ovarian cancer stage III Autoimmune haemolytic anaemia Cutaneous T-cell lymphoma Mucopolysaccharidosis II Progressive multifocal leukoencephalopathy Pseudomyxoma peritonei Cryoglobulinaemia Renal transplant Li-Fraumeni syndrome Follicle centre lymphoma follicular grade I II – III refractory Inclusion body myositis Peripheral T-cell lymphoma unspecified Renal disorder Enteritis Cerebral arteriovenous malformation haemorrhagic More trials…

    Learn about Rare Diseases

    Hereditary optic atrophy – Basic Information Pemphigus – Diagnostics Rhabdomyosarcoma – Life with Disease Noonan syndrome – Treatment Acute respiratory distress syndrome – Trials in Disease Adrenocortical carcinoma – Life with Disease Thrombotic thrombocytopenic purpura – Trials in Disease Breast angiosarcoma metastatic – Basic Information Langerhans cell sarcoma – Basic Information Hyperoxaluria – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Clopidogrel Hydrogen Sulfate Omaveloxolone Pimecrolimus Xevinapant Vincristine Sulfate Lymecycline Acetazolamide Sodium LY3537021 ULVIPRUBART Oxybuprocaine Hydrochloride Oleclumab Vx-522 Fluvastatin Alrefimotide PF-07868489 Abelacimab Taldefgrobep Alfa Maridebart Cafraglutide Dexrazoxane Epinephrine Hydrochloride More therapies…

    Learn about Your Condition

    Electronic cigarette user Fallopian tube cancer stage IV Renal injury Myocarditis Septic shock Abortion threatened Cardiac arrest Urticaria cholinergic Anal cancer Pouchitis Osteosarcoma metastatic Proteus syndrome Testicular germ cell cancer Kawasaki's disease Ataxia telangiectasia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • A study looking at the safety of switching from emicizumab to denecimig in adults and adolescents with haemophilia A with or without inhibitors

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Haemophilia A with anti factor VIII
    • Factor VIII deficiency
    Austria Belgium France Germany Italy Spain

  • A study testing cagrilintide and semaglutide compared to placebo in people with type 2 diabetes not well controlled by diet and exercise

    Not recruiting

    3 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Hungary Italy Poland

  • Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Tozorakimab
    • Salbutamol Sulfate
    Belgium Bulgaria Czechia Denmark Finland Hungary +5

  • A study on ovulation inhibition with norelgestromin patch after missed applications in women who need birth control

    Not recruiting

    2 1 1
    Investigated Drugs:
    • NORELGESTROMIN
    Germany

  • A Study of ALN-6400 Safety and Effectiveness in Adults with Hereditary Hemorrhagic Telangiectasia

    Not recruiting

    1 1
    Investigated Drugs:
    • RNA, (UM-SP-(2′-DEOXY-2′-FLUORO)A-SP-GM-AM-AM-(2′-DEOXY-2′-FLUORO)A-CM-UM-CM-AM-UM-AM-GM-(2′-DEOXY-2′-FLUORO)C-GM-(2′-DEOXY-2′-FLUORO)A-UM-UM-GM-CM-AM-SP-CM-SP-AM), COMPLEX WITH RNA (UM-SP-GM-SP-CM-AM-AM-UM-(2′-DEOXY-2′-FLUORO)C-GM-(2′-DEOXY-2′-FLUORO)C-(2′-DEOXY-2′-FLUORO)U-(2′-DEOXY-2′-FLUORO)A-UM-GM-AM-GM-UM-UM-UM-CM-UM-AM) 3′-[[(2S,4R)-1-[29-[[2-(ACETYLAMINO)-2-DEOXY-Β-D-GALACTOPYRANOSYL]OXY]-14,14-BIS[[3-[[3-[[5-[[2-(ACETYLAMINO)-2-DEOXY-Β-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]PROPYL]AMINO]-3-OXOPROPOXY]METHYL]-1,12,19,25-TETRAOXO-16-OXA-13,20,24-TRIAZANONACOS-1-YL]-4-HYDROXY-2-PYRROLIDINYL]METHYL HYDROGEN PHOSPHATE] (1:1)
    France Germany Spain

  • A Study of Lifileucel with Cyclophosphamide, Fludarabine, and Aldesleukin for Adults with Previously Treated Advanced Melanoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Aldesleukin
    • Cyclophosphamide
    • Fludarabine Phosphate
    France Germany Italy Spain
Previous Page
1 … 940 941 942 943 944 … 1,675
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!